Corvus Pharmaceuticals Stock Discussion

$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Corvus Pharmaceuticals (NASDAQ: CRVS) presented new data at SITC's 39th Annual Meeting showing ciforadenant's potential to overcome resistance to anti-PD1 immunotherapy in metastatic castration resistant prostate cancer (mCRPC). The research, selected as a Top 100 abstract, identified SPP...

$Corvus Pharmaceuticals (CRVS.US)$ Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
3 HOURS AGO, 1:40 PM EST
VIA GLOBENEWSWIRE
BURLINGAME, Calif., Nov. 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new data highlighting the potential of ciforadenant, the Company'...

$Corvus Pharmaceuticals (CRVS.US)$vibrating so much every day… what’s the reasonable price???

$Corvus Pharmaceuticals (CRVS.US)$ 👀 📖
Corvus Pharmaceuticals Inc. carries a moderately high risk level, given its mixed fundamentals and recent volatility. Although positive analyst sentiment and a key drug catalyst suggest potential upward movement, the company's financials signal instability with negative earnings and high cash burn. The stock’s position below its 52-week high with an ongoing sector underperformance adds to the unpredictability. Moreover, the biotechnology sector can present ...

$SKK Holdings (SKK.US)$ $Corvus Pharmaceuticals (CRVS.US)$ are my main 2 as of now

$Corvus Pharmaceuticals (CRVS.US)$ in with a small swing.. keeping my sl tight on this one.

$Corvus Pharmaceuticals (CRVS.US)$ 👀already up above key level $ 8.5 looks good but I don’t like pre- market spikes or breakout lets see what open market signals

$Corvus Pharmaceuticals (CRVS.US)$
The risk associated with trading CRVS stock is moderate due to several contrasting factors. The recent price surge indicates strong market interest and price volatility, posing potential for both significant gains and unexpected reversals. While the upgrade news injects optimism, CRVS's lack of profitability presents a fundamental risk, indicating reliance on external funding rather than internal growth. Additionally, the vibrant trading volume suggests liquidit...